148 related articles for article (PubMed ID: 33022472)
1. Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
Cancer Epidemiol; 2020 Dec; 69():101825. PubMed ID: 33022472
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment.
Villanueva C; Chang J; Bartell SM; Ziogas A; Bristow R; Vieira VM
J Natl Compr Canc Netw; 2019 Nov; 17(11):1318-1329. PubMed ID: 31693984
[TBL] [Abstract][Full Text] [Related]
3. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.
Bristow RE; Chang J; Ziogas A; Anton-Culver H; Vieira VM
Gynecol Oncol; 2014 Jul; 134(1):60-7. PubMed ID: 24680770
[TBL] [Abstract][Full Text] [Related]
4. Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California.
Vieira VM; Villanueva C; Chang J; Ziogas A; Bristow RE
Environ Res; 2017 Jul; 156():388-393. PubMed ID: 28395243
[TBL] [Abstract][Full Text] [Related]
5. Spatial analysis of advanced-stage ovarian cancer mortality in California.
Bristow RE; Chang J; Ziogas A; Gillen DL; Bai L; Vieira VM
Am J Obstet Gynecol; 2015 Jul; 213(1):43.e1-43.e8. PubMed ID: 25644440
[TBL] [Abstract][Full Text] [Related]
6. Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California.
Pfaendler KS; Chang J; Ziogas A; Bristow RE; Penner KR
Obstet Gynecol; 2018 May; 131(5):899-908. PubMed ID: 29630020
[TBL] [Abstract][Full Text] [Related]
7. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
[TBL] [Abstract][Full Text] [Related]
8. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
[TBL] [Abstract][Full Text] [Related]
9. Adherence to treatment guidelines for ovarian cancer as a measure of quality care.
Bristow RE; Chang J; Ziogas A; Anton-Culver H
Obstet Gynecol; 2013 Jun; 121(6):1226-1234. PubMed ID: 23812456
[TBL] [Abstract][Full Text] [Related]
10. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
Bristow RE; Chang J; Villanueva C; Ziogas A; Vieira VM
Obstet Gynecol; 2020 Feb; 135(2):328-339. PubMed ID: 31923082
[TBL] [Abstract][Full Text] [Related]
11. Spatial-Temporal Trends in Ovarian Cancer Outcomes in California.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36238987
[TBL] [Abstract][Full Text] [Related]
12. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
Galvan-Turner VB; Chang J; Ziogas A; Bristow RE
Gynecol Oncol; 2015 Dec; 139(3):495-9. PubMed ID: 26387962
[TBL] [Abstract][Full Text] [Related]
13. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease.
Bristow RE; Chang J; Ziogas A; Randall LM; Anton-Culver H
Gynecol Oncol; 2014 Feb; 132(2):403-10. PubMed ID: 24361578
[TBL] [Abstract][Full Text] [Related]
14. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
[TBL] [Abstract][Full Text] [Related]
15. Disparities in ovarian cancer treatment and overall survival according to race: An update.
Huffman DL; Jayakrishnan TT; Shankar K; Peterson CE; Wegner RE
Gynecol Oncol; 2021 Sep; 162(3):674-678. PubMed ID: 34261593
[TBL] [Abstract][Full Text] [Related]
16. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
[TBL] [Abstract][Full Text] [Related]
17. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
18. Disparities in Receipt of National Comprehensive Cancer Network Guideline-Adherent Care and Outcomes among Women with Triple-Negative Breast Cancer by Race/Ethnicity, Socioeconomic Status, and Insurance Type.
Ubbaonu CD; Chang J; Ziogas A; Mehta RS; Kansal KJ; Zell JA
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067290
[TBL] [Abstract][Full Text] [Related]
19. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on ovarian cancer survival varies by stage.
Bandera EV; Lee VS; Qin B; Rodriguez-Rodriguez L; Powell CB; Kushi LH
Br J Cancer; 2017 Jul; 117(2):282-289. PubMed ID: 28588323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
